Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Treatment of Obsessive Compulsive Disorder
NCT06992999Phase 2Not yet recruiting
- Sponsor
- Francisco A. Moreno
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in obsessive compulsive disorder (OCD), sponsored by Francisco A. Moreno. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT06992999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06992999.